Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics Inc. demonstrated a robust financial performance, reporting a 76% year-over-year revenue growth in Q3 FY25, driven substantially by the integration of the SCN model, which has enhanced revenue generation with minimal additional investment. The company's service revenue exceeded $4.6 million, reflecting a significant increase due to contributions from sleep testing and treatment-center revenues associated with the SCN initiative. Additionally, with continued deployment of service organization teams and strong improvements in patient outcomes, Vivos is well-positioned for sustained revenue growth, particularly as market demand is expected to flourish in North America and the fast-growing Asia Pacific region.

Bears say

Vivos Therapeutics Inc. has experienced a year-over-year revenue decline of 9% in the first half of 2025, primarily attributed to its transition to a new sleep center operation model, which has negatively impacted its financial performance. The company's gross margins dwindled to 55% in the second quarter of 2025, driven by discounting strategies and a shift in product and service offerings, indicating potential challenges in cost management. Additionally, persistent operating losses, negative cash flow, and a significant accumulated deficit exemplify the ongoing uncertainty regarding Vivos' ability to achieve sustainable profitability and maintain growth amidst competitive and regulatory pressures.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.